Hollsteen
← Palantir

Equity incl. NCI

Balance – as of period end · $M

QuartersFiscal years

$MEquity incl. NCI · Q1 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q2 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q3 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q4 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q1 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q2 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q3 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Equity incl. NCI · Q4 2017: −$1.5B · 10-K 0001193125-21-060650 filed Feb 26, 2021Equity incl. NCI · Q1 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Equity incl. NCI · Q2 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Equity incl. NCI · Q3 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Equity incl. NCI · Q4 2018: −$1.8B · 10-K 0001193125-21-060650 filed Feb 26, 2021Equity incl. NCI · Q1 2019: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Equity incl. NCI · Q2 2019: −$1.8B · 10-Q 0001193125-20-292177 filed Nov 13, 2020Equity incl. NCI · Q3 2019: −$1.9B · 10-Q 0001193125-20-292177 filed Nov 13, 2020Equity incl. NCI · Q4 2019: −$2.0B · 10-K 0001193125-21-060650 filed Feb 26, 2021Equity incl. NCI · Q1 2020: −$2.0B · 10-Q 0001193125-21-159222 filed May 12, 2021Equity incl. NCI · Q2 2020: −$1.4B · 10-Q 0001193125-20-292177 filed Nov 13, 2020Equity incl. NCI · Q3 2020: $1.3B · 10-Q 0001193125-20-292177 filed Nov 13, 2020Equity incl. NCI · Q4 2020: $1.5B · 10-K 0001193125-21-060650 filed Feb 26, 2021Equity incl. NCI · Q1 2021: $1.8B · 10-Q 0001193125-21-159222 filed May 12, 2021Equity incl. NCI · Q2 2021: $2.1B · 10-Q 0000950123-21-010430 filed Aug 12, 2021Equity incl. NCI · Q3 2021: $2.2B · 10-Q 0001193125-21-323920 filed Nov 9, 2021Equity incl. NCI · Q4 2021: $2.3B · 10-K 0001193125-22-050913 filed Feb 24, 2022Equity incl. NCI · Q1 2022: $2.4B · 10-Q 0001321655-22-000006 filed May 9, 2022Equity incl. NCI · Q2 2022: $2.3B · 10-Q 0001321655-22-000016 filed Aug 8, 2022Equity incl. NCI · Q3 2022: $2.4B · 10-Q 0001321655-22-000032 filed Nov 7, 2022Equity incl. NCI · Q4 2022: $2.6B · 10-K 0001321655-23-000011 filed Feb 21, 2023Equity incl. NCI · Q1 2023: $2.8B · 10-Q 0001321655-23-000044 filed May 9, 2023Equity incl. NCI · Q2 2023: $3.0B · 10-Q 0001321655-23-000090 filed Aug 8, 2023Equity incl. NCI · Q3 2023: $3.3B · 10-Q 0001321655-23-000118 filed Nov 3, 2023Equity incl. NCI · Q4 2023: $3.6B · 10-K 0001321655-24-000022 filed Feb 20, 2024Equity incl. NCI · Q1 2024: $3.9B · 10-Q 0001321655-24-000071 filed May 7, 2024Equity incl. NCI · Q2 2024: $4.1B · 10-Q 0001321655-24-000135 filed Aug 6, 2024Equity incl. NCI · Q3 2024: $4.6B · 10-Q 0001321655-24-000209 filed Nov 5, 2024Equity incl. NCI · Q4 2024: $5.1B · 10-K 0001321655-25-000022 filed Feb 18, 2025Equity incl. NCI · Q1 2025: $5.5B · 10-Q 0001321655-25-000066 filed May 6, 2025Equity incl. NCI · Q2 2025: $6.0B · 10-Q 0001321655-25-000106 filed Aug 5, 2025Equity incl. NCI · Q3 2025: $6.7B · 10-Q 0001321655-25-000131 filed Nov 4, 2025Equity incl. NCI · Q4 2025: $7.5B · 10-K 0001321655-26-000011 filed Feb 17, 2026Equity incl. NCI · Q1 2026: $8.6B · 10-Q 0001321655-26-000028 filed May 5, 2026Equity incl. NCI · Q2 2026: $9.9B · 10-Q 0001321655-26-000041 filed Aug 4, 2026not reported2,3879,885−1.502Q1 2016Q2 2026Q3 2022
Q3 2022
2,387$M
All values (31)
PeriodValue ($M)Status
Q2 20269,885reported
Q1 20268,556reported
Q4 20257,488reported
Q3 20256,688reported
Q2 20256,026reported
Q1 20255,519reported
Q4 20245,094reported
Q3 20244,591reported
Q2 20244,138reported
Q1 20243,861reported
Q4 20233,561reported
Q3 20233,272reported
Q2 20233,035reported
Q1 20232,803reported
Q4 20222,642reported
Q3 20222,387reported
Q2 20222,349reported
Q1 20222,365reported
Q4 20212,291reported
Q3 20212,248reported
Q2 20212,069reported
Q1 20211,806reported
Q4 20201,523reported
Q3 20201,252reported
Q2 2020−1.399reported
Q1 2020−1.977reported
Q4 2019−1.981reported
Q3 2019−1.893reported
Q2 2019−1.800reported
Q4 2018−1.751reported
Q4 2017Noneerror

11 periods without value hidden · Show gaps with reason · CSV with all sources · Technical ID: equity_total

More metrics for Palantir
Sources & calculation
Value
$2.4B
Period
Q3 2022, ended Sep 30, 2022 · as of Sep 30, 2022 (balance as of date, not a sum)
Source
10-Q, filed Nov 7, 2022 · 0001321655-22-000032
Location
us-gaap:StockholdersEquity
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$2.4BNov 7, 202210-Q 0001321655-22-000032reported · confidence 1. · current